Study title: A double-blind, 2 period, cross-over, placebo-controlled study evaluating three daily doses of 4mg BW825C.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Respiratory Tract Diseases | |||||
Brands: Please see report, Please see report, Please see report, Please see report | |||||
MAH holders: Please see report, Please see report, Please see report, Please see report | |||||
Assessment: | |||||
Active substance: ACRIVASTIN | |||||
ATC code: | |||||
Document link: Study BW825C31UK-Acrivastine.xls | |||||
Document date: 2011-09-07 | |||||
Study number: BW825C31UK | |||||
EudraCT number: | |||||
Scope of study: | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |